Canakinumab for the treatment of TNF-receptor associated periodic syndrome

References

• Williamson LM, Hull D, Mehta R, et al. Familial Hibernian fever. Q J Med. 1982;51:469–480.
   PubMedGoogle Scholar
• Touitou I, Koné-Paut I. Autoinflammatory diseases. Best Pract Res Clin Rheumatol. 2008;22:811–829.
   PubMed Web of Science ®Google Scholar
• Gattorno M, Federici S, Pelagatti MA, et al. Diagnosis and management of autoinflammatory diseases in childhood. J Clin Immunol. 2008;28(Suppl 1):S73–S83.
   PubMed Web of Science ®Google Scholar
• McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97:133–144.
   PubMed Web of Science ®Google Scholar
• Aganna E, Hammond L, Hawkins PN, et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum. 2003;48:2632–2644.
   PubMed Web of Science ®Google Scholar
• Rigante D, Lopalco G, Vitale A, et al. Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. Clin Rheumatol. 2014;33:1197–1207.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Lucherini OM, Iacoponi F, et al. Development and preliminary validation of a diagnostic score for identifying patients affected with adult-onset autoinflammatory disorders. Int J Immunopathol Pharmacol. 2010;23:1133–1141.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Lucherini OM, et al. Childhood versus adulthood-onset autoinflammatory disorders: myths and truths intertwined. Reumatismo. 2013;65:55–62.
   PubMedGoogle Scholar
• Lainka E, Neudorf U, Lohse P, et al. Incidence of TNFRSF1A mutations in German children: epidemiological, clinical and genetic characteristics. Rheumatology (Oxford). 2009;48:987–991.
   PubMed Web of Science ®Google Scholar
• Ravet N, Rouaghe S, Dodé C, et al. Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis. 2006;65:1158–1162.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Papa R, Gerhold K, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. 2014;73(12):2160–2167.
   PubMed Web of Science ®Google Scholar
• Cattalini M, Soliani M, Lopalco G, et al. Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists’ lens. Intern Emerg Med. 2016;11(6):781–791.
   PubMed Web of Science ®Google Scholar
• Hull KM, Wong K, Wood GM, et al. Monocytic fasciitis. A newly recognized clinical feature of tumor necrosis factor receptor dysfunction. Arthritis Rheum. 2002;46:2189–2194.
   PubMed Web of Science ®Google Scholar
• Dode C, Andre M, Bienvenu T, et al. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2002;46:2181–2188.
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, Galon J, Soares M, et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet. 2001;69:301–314.
   PubMed Web of Science ®Google Scholar
• Federici S, Sormani MP, Ozen S, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO) and Eurofever Project. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis 2015;74(5):799–805.
   PubMed Web of Science ®Google Scholar
• Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore). 2002;81:349–368.
   PubMed Web of Science ®Google Scholar
• McDermott MF, Ogunkolade BW, McDermott EM, et al. Linkage of familial Hibernian fever to chromosome 12p13. Am J Hum Genet. 1998;62:1446–1451.
   PubMed Web of Science ®Google Scholar
• Sarrauste de Menthiere C, Terriere S, Pugnere D, et al. INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res. 2003;31:282–285.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Lucherini OM, Cimaz R, et al. Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series. Rheumatol Int. 2012;32:4015–4018.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Lucherini OM, Muscari I, et al. Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev. 2012;12(1):38–43.
   PubMed Web of Science ®Google Scholar
• Rebelo SL, Bainbridge SE, Amel-Kashipaz MR, et al. of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum. 2006;54:2674–2687.
   PubMed Web of Science ®Google Scholar
• Tchernitchko D, Chiminqgi M, Galactéros F, et al. Unexpected high frequency of P46L TNFRSF1A allele in sub-Saharan West African populations. Eur J Hum Genet. 2005;13:513–515.
   PubMed Web of Science ®Google Scholar
• Simon A, Park H, Maddipati R, et al. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci U S A. 2010;107(21):9801–9806.
   PubMed Web of Science ®Google Scholar
• Huggins ML, Radford PM, McIntosh RS, et al. Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: differences between cell types. Arthritis Rheum. 2004;50:2651–2659.
   PubMed Web of Science ®Google Scholar
• Lobito AA, Kimberley FC, Muppidi JR, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood. 2006;108:1320–1327.
   PubMed Web of Science ®Google Scholar
• Magnotti F, Vitale A, Rigante D, et al. The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review. Clin Exp Rheumatol. 2013;31:141–149.
   PubMed Web of Science ®Google Scholar
• Siebert S, Fielding CA, Williams BD, et al. Mutations of the extracellular domain of tumour necrosis factor receptor I causes reduced NF-κB activation due to decreased surface expression. FEBS Lett. 2005;579:5193–5198.
   PubMed Web of Science ®Google Scholar
• Todd I, Radford PM, Draper-Morgan KA, et al. Mutant forms of tumor necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signaling functions but show abnormal behavior. Immunology. 2004;113:65–79.
   PubMed Web of Science ®Google Scholar
• Bulua AC, Simon A, Maddipati R, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). Exp Med. 2011;208:519–533.
   PubMed Web of Science ®Google Scholar
• Dickie LJ, Aziz AM, Savic S, et al. Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis. 2012;71:2035–2043.
   PubMed Web of Science ®Google Scholar
• D’Osualdo A, Ferlito F, Prigione I, et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum. 2006;54:998–1008.
   PubMed Web of Science ®Google Scholar
• Nedjai B, Hitman GA, Yousaf N, et al. Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008;58:273–283.
   PubMed Web of Science ®Google Scholar
• Churchman SM, Church LD, Savic S, et al. A novel TNFRSF1A splice mutation associated with increased nuclear factor kappaB (NF- kappaB) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis. 2008;67:1589–1595.
   PubMed Web of Science ®Google Scholar
• Bachetti T, Chiesa S, Castagnola P, et al. Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann Rheum Dis. 2013;72:1044–1052.
   PubMed Web of Science ®Google Scholar
• Gattorno M, Martini A. Beyond the NLRP3 inflammasome. Autoinflammatory disorders reach adolescence. Arthritis Rheum. 2013;65:1137–1147.
   PubMed Web of Science ®Google Scholar
• Kimberley FC, Lobito AA, Siegel RM, et al. Falling into TRAPS—receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res Ther. 2007;9:217.
   PubMed Web of Science ®Google Scholar
• Greco E, Aita A, Galozzi P, et al. The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathway. Arthritis Res Ther. 2015;17:93.
   PubMed Web of Science ®Google Scholar
• Vitale A, Rigante D, Lucherini OM, et al. Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediators Inflamm. 2013;2013:939847.
   PubMed Web of Science ®Google Scholar
• Ter Haar N, Lachmann H, Özen S, et al. Treatment of, autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. 2013;72:678–685.
   PubMed Web of Science ®Google Scholar
• Vaitla PM, Radford PM, Tighe PJ, et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum. 2011;63:1151–1155.
   PubMed Web of Science ®Google Scholar
• Aganna E, Hawkins PN, Ozen S, et al. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun. 2004;5:289–293.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Rigante D, Lucherini OM, et al. Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Int J Immunopathol Pharmacol. 2010;23:701–707.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Lucherini OM, Galeazzi M, et al. Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment. Clin Exp Rheumatol. 2009;27:890–891.
   PubMed Web of Science ®Google Scholar
• Drewe E, McDermott EM, Powell PT, et al. Powell RJ Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford). 2003;42:235–239.
   PubMed Web of Science ®Google Scholar
• Bulua AC, Mogul DB, Aksentijevich I, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum. 2012;64:908–913.
   PubMed Web of Science ®Google Scholar
• Drewe E, Powell RJ, McDermott EM. Comment on: failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford). 2007;46:1865–1866.
   PubMed Web of Science ®Google Scholar
• Jacobelli S, André M, Alexandra JF, et al. Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS). Rheumatology (Oxford). 2007;46:1211–1212.
   PubMed Web of Science ®Google Scholar
• Nedjai B, Hitman GA, Quillinan N, et al. Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2009;60:619–625.
   PubMed Web of Science ®Google Scholar
• La Torre F, Muratore M, Vitale A, et al. Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Rheumatol Int. 2015;35(11):1943–1947.
   PubMed Web of Science ®Google Scholar
• Simon A, Bodar EJ, van der Hilst JC, et al. Beneficial response to interleukin 1 receptor antagonist in TRAPS. Am J Med. 2004;117:208–210.
   PubMed Web of Science ®Google Scholar
• Gattorno M, Pelagatti MA, Meini A, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor–associated periodic syndrome. Arthritis Rheum. 2008;58:1516–1520.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Lucherini OM, Cimaz R, et al. Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clin Exp Rheumatol. 2010;28(5):802.
   PubMed Web of Science ®Google Scholar
• Krensky AM, Bennett WM, Vincenti F, et al. Immunosuppressants, tolerogens, and immunostimulants. In: Brunton LL, Chabner BA, Knollman BC, editors. Goodman & Gilman’s The pharmacological basis of therapeutics. 12th ed. New York,NY: McGraw-Hill; 2011. p. 1005–1029.
   Google Scholar
• Dhimolea E. Canakinumab. MAbs. 2010;2:3–13.
   PubMed Web of Science ®Google Scholar
• Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet. 2012;51(6):e1–18.
   PubMedGoogle Scholar
• Grom AA. Canakinumab for the treatment of systemic juvenile idiopathic arthritis. Expert Rev Clin Immunol. 2014;10(11):1427–1435.
   PubMed Web of Science ®Google Scholar
• ILARIS, prescribing information. Novartis pharmaceuticals corp. NJ,USA: East Hanover; 2013.
   Google Scholar
• Sun H, Van LM, Floch D, et al. Pharmacokinetics and pharmacodynamics of canakinumab in patients with systemic juvenile idiopathic arthritis. J Clin Pharmacol. 2016;56(12):1516–1527.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557–567.
   PubMed Web of Science ®Google Scholar
• Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201(9):1479–1486.
   PubMed Web of Science ®Google Scholar
• So A, de Smedt T, Revaz S, et al. A pilot study ofIL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002;46(12):3340–3348.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet. 2004;364(9447):1779–1785.
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41(12):2196–2204.
   PubMed Web of Science ®Google Scholar
• Gattorno M, Obici L, Cattalini M, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis. 2017;76(1):173–178. Epub 2016 Jun 7.
   PubMed Web of Science ®Google Scholar
• Brizi MG, Galeazzi M, Lucherini OM, et al. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann Intern Med. 2012;156:907–908.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Rigante D, Vitale A, et al. Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol. 2015;34:807–809.
   PubMed Web of Science ®Google Scholar
• Curtis CD, Fox CC. Treatment of adult hyper-IgD syndrome with canakinumab. J Allergy Clin Immunol Pract. 2015;3(5):817–818.
   PubMed Web of Science ®Google Scholar
• Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10:19.
   PubMed Web of Science ®Google Scholar
• Alpa M, Roccatello D. Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment. Drug Des Devel Ther. 2015;17(9):1983–1987.
   Google Scholar
• Başaran Ö, Uncu N, Çelikel BA, et al. Interleukin 1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol. 2015;25(4):621–624.
   PubMed Web of Science ®Google Scholar
• van der Hilst JCH, Moutschen M, Messiaen PE, et al. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 2016;10:75–80.
   PubMedGoogle Scholar
• ILARIS: Product Information – U.S. Food and Drug Administration (FDA) 2016; Supplement-87. 09/23/2016. Reference ID: 3989830. Available from: www.accessdata.fda.gov/drugsatfda./BLA125319_858687lbl
   Google Scholar
• Torene R, Nirmala N, Obici L, et al. Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis. 2017;76(1):303–309.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–2425.
   PubMed Web of Science ®Google Scholar
• de Benedetti F, Anton J, Ben-Chetrit E, et al. Efficacy and safety of canakinumab in patients with periodic fever syndromes (Colchicine-Resistant FMF, HIDS/MKD AND TRAPS): results from a phase 3, pivotal, umbrella trial. Arthritis Rheumatol. 3205; 68(suppl 10). Available from: http://acrabstracts.org/abstract/efficacy-and-safety-of-canakinumab-in-patients-withperiodic-fever-syndromes-colchicine-resistant-fmf-hidsmkd-and-traps-results-from-a-phase-3-pivotal-umbrella-trial/
   Google Scholar
• de Benedetti F, Frenkel J, Calvo I, et al. Efficacy and safety of canakinumab in patients with colchicine-resistant familial mediterranean fever, hyper-immunoglobulin D Syndrome/Mevalonate kinase deficiency and TNF receptor-associated periodic syndrome: 40 week results from the pivotal Phase 3 umbrella cluster trial. Arthritis Rheumatol. 2016;68(suppl 10):9L.
   Google Scholar
• Ozen S, Kuemmerle-Deschner JB, Cimaz R, et al. International retrospective chart review of treatment patterns in severe FMF, TRAPS and MKD/HIDS. Arthritis Care Res (Hoboken). 2016. [Epub ahead of print]. DOI:10.1002/acr.23120.
   Web of Science ®Google Scholar
• ILARIS: EPAR - Product Information - European Medicines Agency (EMA) 2017; Available from: www.ema.europa.eu/docs/en_GB/./WC500031680.pdf
   Google Scholar
• Agostini L, Martinon F, Burns K et al. NALP3 forms an IL-1β processing inflammasome with increased activity inMuckle-Wells autoinflammatory disorder. Immunity. 2004;20(3):319–325.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29:301–305.
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med. 2006;355:581–592.
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med. 2003;348:2583–2584.
   PubMed Web of Science ®Google Scholar
• Holzinger D, Kessel C, Omenetti A, et al. From bench to bedside and back again: translational research in autoinflammation. Nat Rev Rheumatol. 2015;11(10):573–585.
   PubMed Web of Science ®Google Scholar
• Nowlan ML, Drewe E, Bulsara H, et al. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatol. 2006;45:31–37.
   PubMed Web of Science ®Google Scholar
• Kamata H, Honda S, Maeda S, et al. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell. 2005;120:649–661.
   PubMed Web of Science ®Google Scholar
• Takada Y, Mukhopadhyay A, Kundu GC, et al. Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem. 2003;278:24233–24241.
   PubMed Web of Science ®Google Scholar
• Hosoya T, Mizoguchi F, Hasegawa H, et al. A case presenting with the clinical characteristics of Tumor Necrosis Factor (TNF) Receptor-associated Periodic Syndrome (TRAPS) without TNFRSF1A mutations successfully treated with tocilizumab. Intern Med. 2015;54(16):2069–2072.
   PubMed Web of Science ®Google Scholar
• Akasbi N. Soyfoo MS Successful treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with tocilizumab: A case report. Eur J Rheumatol. 2015;2(1):35–36.
   PubMed Web of Science ®Google Scholar
• Pucino V, Lucherini OM, Perna F, et al. Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome. J Leukoc Biol. 2016;99(5):761–769.
   PubMed Web of Science ®Google Scholar